159 related articles for article (PubMed ID: 15755573)
1. Induction of broadly neutralizing antibodies against measles virus mutants using a polyepitope vaccine strategy.
Bouche FB; Steinmetz A; Yanagi Y; Muller CP
Vaccine; 2005 Mar; 23(17-18):2074-7. PubMed ID: 15755573
[TBL] [Abstract][Full Text] [Related]
2. Neutralization of measles virus wild-type isolates after immunization with a synthetic peptide vaccine which is not recognized by neutralizing passive antibodies.
El Kasmi KC; Fillon S; Theisen DM; Hartter H; Brons NH; Muller CP
J Gen Virol; 2000 Mar; 81(Pt 3):729-35. PubMed ID: 10675410
[TBL] [Abstract][Full Text] [Related]
3. Protection against measles virus-induced encephalitis by anti-mimotope antibodies: the role of antibody affinity.
Olszewska W; Obeid OE; Steward MW
Virology; 2000 Jun; 272(1):98-105. PubMed ID: 10873752
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the contribution of CTL epitopes in the immunobiology of morbillivirus infection.
Beauverger P; Cardoso AI; Daviet L; Buckland R; Wild TF
Virology; 1996 May; 219(1):133-9. PubMed ID: 8623522
[TBL] [Abstract][Full Text] [Related]
5. Neutralising immunogenicity of a polyepitope antigen expressed in a transgenic food plant: a novel antigen to protect against measles.
Bouche FB; Marquet-Blouin E; Yanagi Y; Steinmetz A; Muller CP
Vaccine; 2003 May; 21(17-18):2065-72. PubMed ID: 12706696
[TBL] [Abstract][Full Text] [Related]
6. Priming of measles virus-specific CTL responses after immunization with a CTL epitope linked to a fusogenic peptide.
Partidos CD; Vohra P; Steward MW
Virology; 1996 Jan; 215(1):107-10. PubMed ID: 8553582
[TBL] [Abstract][Full Text] [Related]
7. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes.
Lorin C; Delebecque F; Labrousse V; Da Silva L; Lemonnier F; Brahic M; Tangy F
Vaccine; 2005 Aug; 23(36):4463-72. PubMed ID: 15993518
[TBL] [Abstract][Full Text] [Related]
8. Mapping of B cell epitopes in measles virus nucleocapsid protein.
Zvirbliene A; Kucinskaite I; Sezaite I; Samuel D; Sasnauskas K
Arch Virol; 2007 Jan; 152(1):25-39. PubMed ID: 16944047
[TBL] [Abstract][Full Text] [Related]
9. Protection against measles virus encephalitis by monoclonal antibodies binding to a cystine loop domain of the H protein mimicked by peptides which are not recognized by maternal antibodies.
Ziegler D; Fournier P; Berbers GA; Steuer H; Wiesmüller KH; Fleckenstein B; Schneider F; Jung G; King CC; Muller CP
J Gen Virol; 1996 Oct; 77 ( Pt 10)():2479-89. PubMed ID: 8887481
[TBL] [Abstract][Full Text] [Related]
10. Humoral immune responses to a protective peptide-conjugate against measles after different prime-boost regimens.
Pütz MM; Ammerlaan W; Schneider F; Jung G; Muller CP
Vaccine; 2004 Oct; 22(31-32):4173-82. PubMed ID: 15474707
[TBL] [Abstract][Full Text] [Related]
11. Protective immunity provided by HLA-A2 epitopes for fusion and hemagglutinin proteins of measles virus.
Oh S; Stegman B; Pendleton CD; Ota MO; Pan CH; Griffin DE; Burke DS; Berzofsky JA
Virology; 2006 Sep; 352(2):390-9. PubMed ID: 16781760
[TBL] [Abstract][Full Text] [Related]
12. Recombinant measles AIK-C strain expressing current wild-type hemagglutinin protein.
Kumada A; Komase K; Nakayama T
Vaccine; 2004 Jan; 22(3-4):309-16. PubMed ID: 14670311
[TBL] [Abstract][Full Text] [Related]
13. Japanese encephalitis protein vaccine candidates expressing neutralizing epitope and M.T hsp70 induce virus-specific memory B cells and long-lasting antibodies in swine.
Fei-fei G; Jian W; Feng X; Li-ping S; Quan-yun S; Jin-ping Z; Pu-yan C; Pei-hong L
Vaccine; 2008 Oct; 26(44):5590-4. PubMed ID: 18761388
[TBL] [Abstract][Full Text] [Related]
14. A recombinant rubella virus E1 glycoprotein as a rubella vaccine candidate.
Perrenoud G; Messerli F; Thierry AC; Beltraminelli N; Cousin P; Fasel N; Vallet V; Demotz S; Duchosal MA; Moulon C
Vaccine; 2004 Dec; 23(4):480-8. PubMed ID: 15530696
[TBL] [Abstract][Full Text] [Related]
15. Development of a new neutralization test for measles virus.
Fujino M; Yoshida N; Kimura K; Zhou J; Motegi Y; Komase K; Nakayama T
J Virol Methods; 2007 Jun; 142(1-2):15-20. PubMed ID: 17320979
[TBL] [Abstract][Full Text] [Related]
16. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus.
Brandler S; Lucas-Hourani M; Moris A; Frenkiel MP; Combredet C; Février M; Bedouelle H; Schwartz O; Desprès P; Tangy F
PLoS Negl Trop Dis; 2007 Dec; 1(3):e96. PubMed ID: 18160988
[TBL] [Abstract][Full Text] [Related]
17. Measles viruses of genotype H1 evade recognition by vaccine-induced neutralizing antibodies targeting the linear haemagglutinin noose epitope.
Finsterbusch T; Wolbert A; Deitemeier I; Meyer K; Mosquera MM; Mankertz A; Santibanez S
J Gen Virol; 2009 Nov; 90(Pt 11):2739-2745. PubMed ID: 19625457
[TBL] [Abstract][Full Text] [Related]
18. Mucosal adenovirus-vectored vaccine for measles.
Lobanova LM; Baig TT; Tikoo SK; Zakhartchouk AN
Vaccine; 2010 Nov; 28(48):7613-9. PubMed ID: 20887832
[TBL] [Abstract][Full Text] [Related]
19. Passage in Vero cells alters the characteristics of measles AIK-C vaccine strain.
Uejima H; Nakayama T; Komase K
Vaccine; 2006 Feb; 24(7):931-6. PubMed ID: 16176848
[TBL] [Abstract][Full Text] [Related]
20. Early studies on DNA-based immunizations for measles virus.
Yang K; Mustafa F; Valsamakis A; Santoro JC; Griffin DE; Robinson HL
Vaccine; 1997 Jun; 15(8):888-91. PubMed ID: 9234540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
